The new vaccine, GlaxoSmithKline’s Shingrix, is more than 90% effective in preventing shingles – and that, of course, is its goal. But this research suggests another unexpected advantage. The study ...
Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.
Patients are urged to speak to their GP to check if they are eligible. The Shingrix vaccine can be administered in a pharmacy or a GP but given the expanded criteria, it requires a discussion between ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback